AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca’s SERENA-1 study is a Phase 1 clinical trial investigating the safety and tolerability of AZD9833, a drug for women with ER-positive, HER2-negative advanced breast cancer. The study, officially titled ‘A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer,’ aims to explore the potential of AZD9833 both as a standalone treatment and in combination with other drugs.
The study tests AZD9833 in various combinations, including with palbociclib, everolimus, abemaciclib, capivasertib, ribociclib, and anastrozole. These combinations are designed to assess the drug’s effectiveness in treating endocrine-resistant breast cancer.
The study follows a randomized, sequential intervention model without masking, focusing on treatment as its primary purpose. It includes dose escalation and expansion phases to identify optimal dosing strategies.
Key dates for the study include its start on October 11, 2018, and the latest update on July 8, 2025. These dates indicate the study’s ongoing progress and the importance of continuous monitoring for new developments.
The market implications of this study are significant for AstraZeneca, as positive outcomes could enhance the company’s stock performance and investor confidence. The study’s results could also influence the competitive landscape in the breast cancer treatment market, affecting other companies in the industry.
The SERENA-1 study is currently active but not recruiting, with further updates available on the ClinicalTrials portal.